Beta‐interferon exposure and onset of secondary progressive multiple sclerosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1468-1331|22|6|990-1000

ISSN： 1351-5101

Source： EUROPEAN JOURNAL OF NEUROLOGY, Vol.22, Iss.6, 2015-06, pp. : 990-1000

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon beta‐1b‐induced Sweet's syndrome in a patient with multiple sclerosis

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 4, 2015-04 ,pp. : 456-458

John Wiley & Sons Inc

Access to resources Recommend Favorite

Mitoxantrone in secondary progressive multiple sclerosis: a review of toxicity in 41 patients

By Peak Scott   Tsao-Wei Denice D   Chamberlain Marc C  

Therapy, Vol. 4, Iss. 1, 2007-01 ,pp. : 55-58

Future Medicine

Access to resources Recommend Favorite

Antibodies to Commercially Available Interferon–Beta Molecules in Multiple Sclerosis Patients Treated with Natural Interferon–Beta

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 368-371

Karger

Access to resources Recommend Favorite

Glatiramer acetate versus interferon Beta-1a for subcutaneous administration: Comparison of outcomes among multiple sclerosis patients

By Castelli-Haley Jane  

Advances in Therapy, Vol. 25, Iss. 8, 2008-08 ,pp. : 830-830

Springer Publishing Company

Access to resources Recommend Favorite

Development of systemic sarcoidosis and xanthoma planum during multiple sclerosis treatment with interferon‐beta 1a: Case Report

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 5, 2015-05 ,pp. : e140-e145

John Wiley & Sons Inc

Access to resources Recommend Favorite